Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 2
Submit an article Journal homepage
59
Views
0
CrossRef citations to date
0
Altmetric
Original Research: Oncology

Efficacy and risk of osteonecrosis of the jaw for pamidronate, zoledronic acid, and denosumab in comparison to alendronate in multiple myeloma patients

Micah Brownea University of Texas Medical Branch at Galveston, Galveston, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0004-2792-9167
, BSORCID Icon,
Brittany Milesb Department of Radiology, Baylor University Medical Center, Dallas, Texas, USA
, MD &
James Mackeyc Department of Oncology, Baylor University Medical Center, Dallas, Texas, USA
, MD
Pages 227-229 | Received 31 Aug 2023, Accepted 07 Dec 2023, Published online: 08 Jan 2024

  • Key Statistics for Multiple Myeloma. 2023. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html. Accessed May 22, 2023.
  • Xiao R, Miller JA, Margetis K, et al. Radiographic progression of vertebral fractures in patients with multiple myeloma. Spine J. 2016;16(7):822–832. doi:10.1016/j.spinee.2015.10.033.
  • Zhang F, Zhuang J. Pathophysiology and therapeutic advances in myeloma bone disease. Chronic Dis Transl Med. 2022;8(4):264–270. doi:10.1002/cdt3.35.
  • Oranger A, Carbone C, Izzo M, Grano M. Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol. 2013;2013:289458–289411. doi:10.1155/2013/289458.
  • Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer. 2008;98(11):1736–1740. doi:10.1038/sj.bjc.6604382.
  • Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24(6):945–952. doi:10.1200/JCO.2005.04.2465.
  • Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016;27(3):367–375. doi:10.1111/clr.12556.
  • Ferreira LH Jr, Mendonça KD Jr, Chaves de Souza J, et al. Bisphosphonate-associated osteonecrosis of the jaw. Minerva Dent Oral Sci. 2021;70(1):49–57. doi:10.23736/S2724-6329.20.04306-X.
  • Diel I, Ansorge S, Hohmann D, Giannopoulou C, Niepel D, Intorcia M. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Support Care Cancer. 2020;28(11):5223–5233. doi:10.1007/s00520-020-05357-5.
  • Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD003188. doi:10.1002/14651858.CD003188.pub4.
  • Raje NS, Bhatta S, Terpos E. Role of the RANK/RANKL pathway in multiple myeloma. Clin Cancer Res. 2019;25(1):12–20. doi:10.1158/1078-0432.CCR-18-1537.
  • Zijlstra H, Wolterbeek N, Ponds NHM, et al. The incidence of vertebral compression fractures and spinal instability in newly diagnosed multiple myeloma patients. J Orthop. 2023;38:62–67. doi:10.1016/j.jor.2023.03.008.
  • Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487–493. doi:10.1359/JBMR.041131.
  • Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn. 2011;11(6):593–603. doi:10.1586/erm.11.44.
  • Miller JA, Bowen A, Morisada MV, et al. Radiologic and clinical characteristics of vertebral fractures in multiple myeloma. Spine J. 2015;15(10):2149–2156. doi:10.1016/j.spinee.2015.05.026.
  • Thorsteinsdottir S, Gislason G, Aspelund T, et al. Fractures and survival in multiple myeloma: results from a population-based study. Haematologica. 2020;105(4):1067–1073. doi:10.3324/haematol.2019.230011.
  • Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–1867. doi:10.1002/cncr.22991.
  • Parrondo RD, Sher T. Prevention of skeletal related events in multiple myeloma: focus on the RANK-L pathway in the treatment of multiple myeloma. Onco Targets Ther. 2019;12:8467–8478. doi:10.2147/OTT.S192490.
  • Krstevska S, Stavric SG, Cevrevska L, et al. Osteonecrosis of the jaw after bisphosphonates treatment in patients with multiple myeloma. Med Arch. 2015;69(6):367–370. doi:10.5455/medarh.2015.69.367-370.
  • Gupta M, Gupta N. Bisphosphonate related jaw osteonecrosis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.